|
1.
|
|
12 p, 1.1 MB |
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL : primary analysis of the CAPTIVATE FD cohort
/
Tam, Constantine S (University of Melbourne) ;
Allan, John N (Weill Cornell Medicine) ;
Siddiqi, Tanya (City of Hope National Medical Center) ;
Kipps, Thomas J. (University of California San Diego) ;
Jacobs, Ryan (Levine Cancer Institute) ;
Opat, Stephen (Monash University) ;
Barr, Paul M. (University of Rochester Medical Center) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Trentin, Livio (University of Padova) ;
Bannerji, Rajat (Rutgers Cancer Institute of New Jersey) ;
Jackson, Sharon (Middlemore Hospital) ;
Kuss, Bryone J. (Flinders University and Medical Center) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Szafer-Glusman, Edith (Pharmacyclics LLC. an AbbVie Company) ;
Russell, Kristin (Pharmacyclics LLC. an AbbVie Company) ;
Zhou, Cathy (Pharmacyclics LLC. an AbbVie Company) ;
Ninomoto, Joi (Pharmacyclics LLC. an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ;
Wierda, William G. (DepaUniversity of Texas MD Anderson Cancer Center) ;
Ghia, Paolo (IRCCS Ospedale San Raffaele) ;
Universitat Autònoma de Barcelona
CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration (FD) treatment with ibrutinib plus venetoclax are reported. [...]
2022 -  10.1182/blood.2021014488
Blood, Vol. 139 Núm. 22 (february 2022) , p. 3278-3289
|
|
|
2.
|
|
11 p, 1.9 MB |
Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years : a plain language summary
/
Barr, Paul M. (University of Rochester Medical Center, USA) ;
Owen, Carolyn (University of Calgary, Canada) ;
Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ;
Bairey, Osnat (Rabin Medical Center, Petah Tikva, Israel) ;
Burger, Jan A (University of Texas MD Anderson Cancer Center, Houston, USA) ;
Hillmen, Peter (The Leeds Teaching Hospitals, St James Institute of Oncology, Leeds, UK) ;
Dearden, Claire (The Royal Marsden Hospital, London, UK) ;
Grosicki, Sebastian (Silesian Medical University, Katowice, Poland) ;
McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ;
Li, Jian Yong (Jiangsu Province Hospital, Nanjing, China) ;
Offner, Fritz (Universitair Ziekenhuis Gent, Belgium) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jermain, Mandy (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Hsu, Emily (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Szoke, Anita (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Kipps, Thomas J. (UCSD Moores Cancer Center, San Diego, USA) ;
Ghia, Paolo (Università Vita-Salute San Raffaele &IRCCS Ospedale San Raffaele, Milan, Italy)
What is this summary about? This is a plain language summary of a publication describing long-term results from the RESONATE-2 study with up to 8 years of follow-up. The original paper was published in Blood Advances in June 2022. [...]
2022 - 10.2217/fon-2022-0898
Future oncology (London, England), Vol. 18 Núm. 37 (january 2022)
|
|
|
3.
|
|
9 p, 996.2 KB |
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : Extended phase 3 results from RESONATE-2
/
Barr, Paul M. (University of Rochester) ;
Robak, Tadeusz (Medical University of Lodz) ;
Owen, Carolyn (Tom Baker Cancer Centre) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Bairey, Osnat (Sackler Faculty of Medicine. Tel Aviv University) ;
Bartlett, Nancy L. (Washington University School of Medicine) ;
Burger, Jan A. (University of Texas MD Anderson Cancer Center) ;
Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Devereux, Stephen (Kings College Hospital) ;
Grosicki, Sebastian (School of Public Health. Silesian Medical University) ;
McCarthy, Helen (Royal Bournemouth Hospital) ;
Li, Jianyong (Jiangsu Province Hospital) ;
Simpson, David (North Shore Hospital) ;
Offner, Fritz (Universitair Ziekenhuis Gent) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Zhou, Cathy (Pharmacyclics. LLC an AbbVie Company) ;
Styles, Lori (Pharmacyclics. LLC an AbbVie Company) ;
James, Danelle (Pharmacyclics. LLC an AbbVie Company) ;
Kipps, Thomas J (University of California,San Diego. Moores Cancer Center) ;
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ;
Universitat Autònoma de Barcelona
Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic Rleukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with chronic lymphocytic leukemia. [...]
2018 - 10.3324/haematol.2018.192328
Haematologica, Vol. 103 Núm. 9 (31 2018) , p. 1502-1510
|
|
|
4.
|
|
9 p, 698.5 KB |
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib : A GIMEMA, ERIC and UK CLL FORUM study
/
Cuneo, Antonio (St. Anna University Hospital) ;
Follows, George (Cambridge University Hospitals NHS Foundation Trust (Anglaterra)) ;
Rigolin, Gian Matteo (St. Anna University Hospital) ;
Piciocchi, Alfonso (Italian Group for Adult Hematologic Diseases (GIMEMA)) ;
Tedeschi, Alessandra (Niguarda Cancer Center) ;
Trentin, Livio (University of Padua) ;
Perez, Angeles Medina (Hospital Costa del Sol (Marbella)) ;
Coscia, Marta (University of Turin) ;
Laurenti, Luca (Policlinico A. Gemelli) ;
Musuraca, Gerardo (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)) ;
Farina, Lucia (Fondazione IRCCS Istituto Nazionale Tumori) ;
Delgado, Alfredo Rivas (Hospital Clínic i Provincial de Barcelona) ;
Orlandi, Ester Maria (Fondazione IRCCS Policlinico San Matteo) ;
Galieni, Piero (Ospedale C. e G. Mazzoni) ;
Mauro, Francesca Romana ("Sapienza" University) ;
Visco, Carlo (San Bortolo Hospital) ;
Amendola, Angela (San Carlo Hospital) ;
Billio, Atto (Azienda Sanitaria dell'Alto Adige) ;
Marasca, Roberto (University of Modena and Reggio Emilia) ;
Chiarenza, Annalisa (Azienda Universitaria Ospedaliera Policlinico Vittorio Emanuele) ;
Meneghini, Vittorio (University Hospital) ;
Ilariucci, Fiorella (Arcispedale S. Maria Nuova) ;
Marchetti, Monia (Cardinal Massaia Hospital) ;
Molica, Stefano (Azienda Ospedaliera Pugliese Ciaccio) ;
Re, Francesca (University Hospital) ;
Gaidano, Gianluca (Università del Piemonte Orientale Amedeo Avogadro) ;
Gonzalez, Marcos (Hospital Universitari IBSAL i CIBERONC) ;
Forconi, Francesco (University Hospital National Health Service Trust) ;
Ciolli, Stefania (Careggi Hospital) ;
Cortelezzi, Agostino (University of Milan) ;
Montillo, Marco (Niguarda Cancer Center) ;
Smolej, Lukas (University Hospital) ;
Schuh, Anna (Oxford University Hospitals NHS Foundation Trust) ;
Eyre, Toby A. (Oxford University Hospitals NHS Foundation Trust) ;
Kennedy, Ben (University Hospitals of Leicester NHS Trust) ;
Bowles, Kris M. (Norwich Medical School) ;
Vignetti, Marco (Italian Group for Adult Hematologic Diseases (GIMEMA)) ;
De La Serna, Javier (Hospital 12 de Octubre (Madrid)) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Foà, Robin ("Sapienza" University) ;
Ghia, Paolo (IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University) ;
Universitat Autònoma de Barcelona
We performed an observational study on the efficacy of bendamustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. [...]
2018 - 10.3324/haematol.2018.189837
Haematologica, Vol. 103 Núm. 7 (march 2018) , p. 1209-1217
|
|
|
5.
|
|
9 p, 1.3 MB |
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia : A cross-trial comparison of phase 3 studies
/
Robak, Tadeusz (Medical University of Lodz) ;
Burger, Jan A. (The University of Texas MD Anderson Cancer Center) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Barr, Paul M. (University of Rochester Cancer Center) ;
Owen, Carolyn (University of Calgary) ;
Bairey, Osnat (Tel Aviv University) ;
Hillmen, Peter (St. James's Institute of Oncology) ;
Simpson, David (North Shore Hospital) ;
Grosicki, Sebastian (Silesian Medical University) ;
Devereux, Stephen (King's College Hospital NHS Foundation Trust) ;
McCarthy, Helen (Royal Bournemouth Hospital) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Quach, Hang (St. Vincent's Hospital) ;
Gaidano, Gianluca (Amedeo Avogadro University of Eastern Piedmont) ;
Maslyak, Zvenyslava (Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine) ;
Stevens, Don A. (Norton Cancer Institute) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Gill, Devinder S. (Princess Alexandra Hospital) ;
Flinn, Ian W. (Sarah Cannon Research Institute/Tennessee Oncology) ;
Gribben, John G. (Queen Mary University of London) ;
Mokatrin, Ahmad (Pharmacyclics LLC. an AbbVie Company) ;
Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ;
Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Kipps, Thomas J (University of California San Diego) ;
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ;
Universitat Autònoma de Barcelona
Chemoimmunotherapy (CIT) and targeted therapy with single-agent ibrutinib are both recommended first-line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. [...]
2018 - 10.1002/ajh.25259
American Journal of Hematology, Vol. 93 Núm. 11 (november 2018) , p. 1402-1410
|
|
|
6.
|
|
25 p, 1.7 MB |
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
/
O'Brien, Susan (University of California) ;
Hillmen, Peter (St. James University Hospital) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Barr, Paul M (University of Rochester Cancer Center) ;
Fraser, Graeme (McMaster University (Canadà)) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Burger, Jan A. (University of Texas MD Anderson Cancer Center) ;
Dilhuydy, Marie-Sarah (Centre Hospitalier Universitaire Hopitaux de Bordeaux) ;
Hess, Georg (Universitats Medizin Mainz) ;
Moreno Atanasio, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Cramer, Paula (University of Cologne) ;
Liu, Emily (Pharmacyclics LLC. an AbbVie Company) ;
Chang, Stephen (Pharmacyclics LLC. an AbbVie Company) ;
Vermeulen, Jessica (Janssen Research & Development) ;
Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ;
Howes, Angela (Janssen Research & Development) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Patel, Kalpesh (Janssen Pharmaceuticals. Inc) ;
Graef, Thorsten (Pharmacyclics LLC. an AbbVie Company) ;
Valentino, Rudolph (Pharmacyclics LLC. an AbbVie Company) ;
Universitat Autònoma de Barcelona
Ibrutinib, a Bruton's tyrosine kinase inhibitor, has become a standard treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The present pooled safety analysis of 4 randomized controlled studies demonstrated a favorable benefit/risk profile for ibrutinib in patients with CLL/SLL and mantle cell lymphoma. [...]
2018 - 10.1016/j.clml.2018.06.016
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18 Núm. 10 (october 2018) , p. 648-657.e15
|
|
|
7.
|
|
13 p, 1.6 MB |
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab : final analysis of the randomized, phase III iLLUMINATE trial
/
Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Greil, Richard (Salzburg Cancer Research Institute-CCCIT (Àustria)) ;
Demirkan, Fatih (Dokuz Eylul University (Turquía)) ;
Tedeschi, Alessandra (Niguarda Ca Granda Hospital (Itàlia)) ;
Anz, Bertrand (Tennessee Oncology (Estats Units)) ;
Larratt, Loree (University of Alberta Hospital (Canadà)) ;
Simkovic, Martin (University Hospital and Medical School Hradec (Txèquia)) ;
Novak, Jan (Charles University (Txèquia)) ;
Strugov, Vladimir (Almazov National Medical Research Centre (Rússia)) ;
Gill, Devinder (Princess Alexandra Hospital) ;
Gribben, John G. (Barts Cancer Institute) ;
Kwei, Kevin (Pharmacyclics LLC) ;
Dai, Sandra (Pharmacyclics LLC) ;
Hsu, Emily (Pharmacyclics LLC) ;
Dean, James P. (Pharmacyclics LLC) ;
Flinn, Ian W. (Sarah Cannon Research Institute) ;
Universitat Autònoma de Barcelona
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. [...]
2022 - 10.3324/haematol.2021.279012
Haematologica, Vol. 107 (january 2022) , p. 2108-2120
|
|
|
8.
|
|
11 p, 1.4 MB |
Up to 8-year follow-up from RESONATE-2 : first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
/
Barr, Paul M. (Clinical Trials Office. Wilmot Cancer Institute. University of Rochester Medical Center) ;
Owen, Carolyn (Division of Hematology & Hematological Malignancies. Tom Baker Cancer Centre. University of Calgary) ;
Robak, Tadeusz (Medical University of Lodz) ;
Tedeschi, Alessandra (Department of Hematology. Azienda Socio Sanitaria Territoriali Grande Ospedale Metropolitano Niguarda) ;
Bairey, Osnat (Department of Hematology. Rabin Medical Center) ;
Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ;
Hillmen, Peter (Department of Haematology. The Leeds Teaching Hospitals. St. James Institute of Oncology) ;
Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Cente) ;
Dearden, Claire (Haemato-Oncology Department. The Royal Marsden Hospital) ;
Grosicki, Sebastian (Department of Hematology and Cancer Prevention. School of Public Health. Silesian Medical University) ;
McCarthy, Helen (Royal Bournemouth General Hospital. Haematology Department) ;
Li, Jian-Yong (Jiangsu Province Hospital. Department of Hematology) ;
Offner, Fritz (Universitair Ziekenhuis Gent. Department of Clinical Hematology) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Zhou, Ccathy (Biostatistics. Pharmacyclics LLC. An AbbVie Company) ;
Hsu, Emily (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ;
Szoke, Anita (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ;
Kipps, Thomas J. (University of California San Diego. Department of Medicine. Moores Cancer Center) ;
Ghia, Paolo (Università Vita-Salute San Raffaele. Department of Onco-Hematology. Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele) ;
Universitat Autònoma de Barcelona
2022 - 10.1182/bloodadvances.2021006434
Blood advances, Vol. 6 Núm. 11 (june 2022) , p. 3440-3450
|
|
|
9.
|
|
15 p, 664.9 KB |
Ibrutinib plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia : Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
/
Wierda, W. G. (University of Texas.) ;
Allan, J. N. (Weill Cornell Medicine) ;
Siddiqi, Tanya (City of Hope National Medical Center) ;
Kipps, T. J. (UCSD. Moores Cancer Center) ;
Opat, S. (Monash University) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Badoux, X. C. (Ministry of Health) ;
Kuss, B. J. (Flinders University. Medical Centre) ;
Jackson, Sharon (Middlemore Hospital) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Jacobs, R. M. D. (Levine Cancer Institute) ;
Pagel, J. M. (Swedish Cancer Institute. Center for Blood Disorders and Stem Cell Transplantation) ;
Flinn, I. (Sarah Cannon Research Institute. Tennessee Oncology) ;
Pak, Y. (Pharmacyclics LLC. AbbVie Company) ;
Zhou, Cathy (Pharmacyclics LLC. AbbVie Company) ;
Szafer-Glusman, E. (Pharmacyclics LLC. AbbVie Company) ;
Ninomoto, J. (Pharmacyclics LLC. AbbVie Company) ;
Dean, James P (Pharmacyclics LLC. AbbVie Company) ;
James, D. F. (Pharmacyclics LLC. AbbVie Company) ;
Ghia, Paolo (Università Vita-Salute San Raffaele. IRCCS Ospedale San Raffaele) ;
Tam, C. S. (Peter MacCallum Cancer Center. St Vincent's Hospital. University of Melbourne) ;
Universitat Autònoma de Barcelona
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). [...]
2021 - 10.1200/JCO.21.00807
Journal of Clinical Oncology, Vol. 39 Núm. 34 (january 2021) , p. 3853-3865
|
|
|
10.
|
|
10 p, 631.8 KB |
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL : analysis from the iLLUMINATE study
/
Greil, Richard (Salzburg Cancer Research Institute-CCCIT, Cancer Cluster Salzburg. IIIrd Medical Department Paracelsus Medical University) ;
Tedeschi, Alessandra (Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Anz, Bertrand (Tennessee Oncology. Department of Medical Oncology) ;
Larratt, Loree (University of Alberta Hospital. Department of Clinical Hematology) ;
Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ;
Gill, Devinder (Princess Alexandra Hospital. Department of Clinical Hematology) ;
Gribben, John G. (Queen Mary University of London, Barts Cancer Institute. Centre for Haemato-Oncology) ;
Flinn, Ian W. (Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology. Center for Blood Cancers) ;
Wang, Zhengyuan (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ;
Cheung, Leo W. K. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ;
Nguyen, Aaron N. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ;
Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company. Biostatistics) ;
Styles, Lori (Pharmacyclics LLC, an AbbVie Company. Clinical Science) ;
Demirkan, Fatih (Dokuz Eylül University. Department of Hematology) ;
Universitat Autònoma de Barcelona
The online version contains supplementary material available at 10. 1007/s00277-021-04536-6.
2021 - 10.1007/s00277-021-04536-6
Annals of Hematology, Vol. 100 (may 2021) , p. 1733-1742
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
